Protein engineering of cytochromes P-450

Biochimica et Biophysica Acta - Protein Structure and Molecular Enzymology

Volumn 1543, Issue 2, 2000, Pages 383-407

  Miles, C S ^a   Ost, T W B ^a   Noble, M A ^a   Munro, A W ^a   Chapman, S K ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Chimeragenesis; Electron transfer; Genetic fusion; P 450; Protein engineering; Substrate specificity

Indexed keywords

CYTOCHROME B5; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 ISOENZYME; CYTOCHROME P450 REDUCTASE; LACTATE DEHYDROGENASE (CYTOCHROME); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

CHIMERA; ELECTRON TRANSPORT; ENZYME ACTIVE SITE; ENZYME MODIFICATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENE FUSION; GENETIC ENGINEERING; MEMBRANE BINDING; PRIORITY JOURNAL; REVIEW;

EID: 0034731474     PISSN: 01674838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4838(00)00236-3     Document Type: Review

References (153)

1. The P450 superfamily: Update on new sequences, gene-mapping, accession numbers, early trivial names of enzymes, and nomenclature
2. Bacterial cytochromes P450
3. Twenty-five years of P450cam research
4. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
5. Cloning of a potential cytochrome P450 from the archaeon Sulfolobus solfataricus
6. Crystal structure of nitric oxide reductase from denitrifying fungus Fusarium oxysporum
7. Active site topology of bovine cholesterol side-chain cleavage cytochrome P450 scc and evidence for interaction of tyrosine 94 with cholesterol
8. Interaction of polycyclic aromatic hydrocarbons with human cytochrome P450 1A1: A CO flash photolysis study
9. Mammalian microsomal cytochrome P450 monooxygenase: Structural adaptations for membrane binding and functional diversity
10. Crystallization and preliminary X-ray diffraction analysis of a cytochrome P450 (CYP119) from Sulfolobus solfataricus
11. Crystal structure of substrate-free Pseudomonas putida cytochrome P450
12. Crystal structure of hemoprotein domain of P450 BM3, a prototype for microsomal P450s
13. Crystal structure and refinement of cytochrome P450terp at 2.3Å resolution
14. Structure of cytochrome P450 eryF involved in erythromycin biosynthesis
15. High resolution crystal structure of cytochrome P450cam
16. The structure of the cytochrome P450 BM3 heme domain complexed with the fatty acid substrate, palmitoleic acid
17. Crystallisation and preliminary X-ray diffraction analysis of P450 sca2 from Streptomyces carbophilus involved in production of pravastatin sodium, a tissue-selective inhibitor of HMG-CoA reductase
18. Inhibitor-induced conformational change in P450cam
19. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences
20. Engineering mouse P450coh to a novel corticosterone 15-α-hydroxylase and modelling steroid binding orientation in the substrate pocket
21. Role of residue 480 in substrate specificity of cytochrome P450 2B5 and 2B11
22. A single amino acid substitution confers progesterone 6β-hydroxylase activity to rabbit cytochrome P450 2C3
23. A predicted 3-D structure of human cytochrome P450-implications for substrate specificity
24. Application of 3-Dimensional homology modelling of cytochrome P450 2B1 for interpretation of site-directed mutagenesis results
25. Molecular modelling of the 3-D structure of cytochrome P450scc
26. Structure and function of cytochromes P450: A comparative analysis of three crystal structures
27. Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity
28. Molecular modelling of CYP4A subfamily members based on sequence homology with CYP102
29. A three-dimensional model of aromatase cytochrome P450
30. Site-directed mutagenesis as a tool for molecular modeling of cytochrome P450 2B1
31. Molecular modeling of cytochrome P450 2B1: Mode of membrane insertion and substrate specificity
32. Molecular modeling of cytochrome P450 3A4
33. Enzymatic determinants of the substrate specificity of CYP2C9: Role of the B′-C loop residues in providing the π-stacking anchor site for warfarin binding
34. Engineering microsomal P-450 2C5 to be a soluble, monomeric enzyme: Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding
35. Molecular recognition in cytochrome P450: Mechanism for the control of uncoupling reactions
36. The catalytic oxidation of linear and branched alkanes by cytochrome P450cam
37. The oxidation of naphthalene and pyrene by cytochrome P450cam
38. Cytochrome P450cam monooxygenase can be redesigned to catalyze the regioselective aromatic hydroxylation of diphenylmethane
39. Mutations of phenyl-alanine 193 in the putative substrate access channel alter the substrate specificity of cytochrome P450 cam
40. Engineering the specificity of Bacillus megaterium P450 BM3: Hydroxylation of alkyl triammonium compounds
41. Roles of key active-site residues in flavocytochrome P450 BM3
42. A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation
43. The catalytic mechanism of cytochrome P450 BM3 involves a 6 angstrom movement of the bound substrate upon reduction
44. Glu-320 and Asp-323 are determinants of the CYP4A1 hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole
45. Isolation, heterologous expression and functional characterisation of a novel cytochrome P450 3A enzyme from a canine cDNA library
46. Human cytochrome P450 enzymes
47. Human liver microsomal steroid metabolism-identification of the major microsomal steroid-hormone 6-beta-hydroxylase cytochrome P450 enzyme
48. Evidence for cytochrome P450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver
49. Modulation of rabbit and human hepatic cytochrome P450 catalysed steroid hydroxylations by α-naphthoflavone
50. Cooperativity in oxidations catalysed by cytochrome P450 3A4
51. Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4
52. Molecular modelling of CYP3A4 from an alignment with CYP102: Identification of key interactions between putative active site residues and CYP3A-specific chemicals
53. Analysis of human cytochrome P450 3A4 cooperativity: Construction and characterisation of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics
54. Analysis of four residues within substrate recognition site 4 of cytochrome P450 3A4: Role of steroid hydroxylase activity and α-naphthoflavone stimulation
55. Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity
56. Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis
57. The importance of SRS-1 residues in catalytic specificity of cytochrome P450 3A4
58. Structure-function relationships of human liver cytochromes P450 3A: Aflatoxin B1 metabolism as a probe
59. Identification by in vitro mutagenesis of the interaction of two segments of C2MstC1, a chimera of cytochromes P450 2C2 and P450 2C1
60. Molecular basis for the differences in lidocaine binding and regioselectivity of oxidation by cytochrome P450 2B1 and 2B2
61. Elucidation of amino acid residues critical for unique activities of rabbit cytochrome P450 2B5 using hybrid enzymes and reciprocal site-directed mutagenesis with rabbit cytochrome P450 2B4
62. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen
63. Identification of residues 99, 220 and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity
64. Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19
65. Use of chimeric enzymes and site-directed mutagenesis for identification of three key residues responsible for differences in steroid hydroxylation between canine cytochromes P450 3A12 and 3A26
66. Mutual conversion of fatty-acid substrate specificity by a single amino acid exchange at position 527 in P450Cm2 and P450Alk3A
67. Inter-individual variations in human liver cytochrome P450 enzymes involved in the oxidation of drug, carcinogens and toxic chemicals
68. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450Iic cub-family
69. Biochemistry and molecular biology of the human CYP2C subfamily
70. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P4502C
71. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans
72. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9
73. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specificity inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9
74. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
75. The sequence homologies of cytochromes P450 and active-site geometries
76. Comparison of two cytochromes P450 from Candida maltosa: Primary structure, substrate specificities and effects of their expression in Saccharomyces cerevisiae on the proliferation of the endoplasmic reticulum
77. Mutual conversion of fatty acid substrate specificity by a single amino acid exchange at position 527 in P450Cm2 and P450Alk3A
78. Random chimeragenesis of G-protein-coupled receptors-mapping the affinity of the cAMP chemoattractant receptors in Dictyostelium
79. Identification of functional domains of adenylyl-cyclase using in-vivo chimeras
80. Studies of distant members of the P450 superfamily (P450scc and P450c27) by random chimeragenesis
81. The use of random chimeragenesis to study structure/function properties of rat and human P450c17
82. Design of a novel P450: A functional bacterial-human cytochrome P450 chimera
83. The amino-terminal 29 amino acids of cytochrome P450 2C1 are sufficient for retention in the endoplasmic reticulum
84. The N-terminal hydrophobic domain of P450c21 is required for membrane insertion and enzyme stability
85. N-terminal modifications that alter P450 membrane targeting and function
86. 2-terminal-modified microsomal P450 in E. coli
87. Determination of membrane-bound fragments of cytochrome P450 2B4
88. Substitutions in the C-terminal portion of the catalytic domain partially reverse assembly defects introduced by mutations in the N-terminal linker sequence of cytochrome P450 2C2
89. Molecular engineering of microsomal P450 2A4 to a stable, water-soluble enzyme
90. Generation of a complete, soluble, and catalytically active sterol 14α-demethylase-reductase complex
91. NADPH-flavodoxin reductase and flavodoxin from Escherichia coli: Characteristics as a soluble microsomal P450 reductase
92. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4 or 3A5: Catalytic activities and mutagenicity studies
93. Use of heterologous expression systems to study autoimmune drug-induced hepatitis
94. Designer membranes-construction of a cell containing multiple membrane-bound cytochromes P450
95. Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modifications of its N-terminus
96. A thermodynamic model of regulation: Modulation of redox equilibria in camphor monooxygenase
97. Redox control of the catalytic cycle of flavocytochrome P450 BM3
98. Cytochrome P450scc-substrate interactions: Studies of binding and catalytic activity using hydroxycholesterols
99. Adrenodoxin reductase-adrenodoxin complex: Flavin to iron-sulfur electron transfer as the rate-limiting step in the NADPH-cytochrome c reductase reaction
100. Cytochrome P-450scc-adrenodoxin interactions: Ionic effects on binding, and regulation of cytochrome reduction by bound steroid substrates
101. 5-cytochrome P450 cam electron transfer complex
102. The formation of binary and ternary complexes of cytochrome P450 scc with adrenodoxin and adrenodoxin reductase-adrenodoxin complex
103. Single turnover kinetics of the reaction between oxycytochrome P450 cam and reduced putidaredoxin
104. Significant contribution of arginine 112 and its positive charge of Pseudomonas putida P450 cam in the electron transport from putidaredoxin
105. Genetic variants in the putidaredoxin-cytochrome P450 cam electron transfer complex: Identification of the residue responsible for redox-state-dependent conformers
106. Role of Arg 112 of cytochrome P450 cam in the electron transfer from reduced putidaredoxin-analyses with site-directed mutants
107. Roles of negatively charged surface residues of putidaredoxin in interactions with redox partners in P450cam monooxygenase system
108. Roles of valine 98 and glutamic acid 72 of putidaredoxin in the electron transfer complexes with NADH-putidaredoxin reductase and P450 cam
109. Binding and electron transfer between putidaredoxin and cytochrome P450 cam. Theory and experiments
110. A role for putidaredoxin COOH-terminus in P450 cam (cytochrome m) hydroxylations
111. Electron transport in cytochromes P450 by covalent switching
112. The role of tryptophan 97 of cytochrome P450 BM3 from Bacillus megaterium in catalytic function. Evidence against the 'covalent switching' hypothesis of P450 electron transfer
113. 5
114. 5 augments the 17, 20-lyase activity of human P450 c17 without direct electron transfer
115. 5
116. The cytochrome P450 cam binding surface as defined by site-directed mutagenesis and electrostatic modelling
117. 5 and cytochrome P450 reductase
118. 5
119. Identification and characterisation of two functional domains in cytochrome P450 BM3, a catalytically self-sufficient monooxygenase induced by barbiturates in Bacillus megaterium
120. Domains of the catalytically self-sufficient cytochrome P450 BM3-genetic construction, overexpression, purification and spectroscopic characterisation
121. The domain architecture of cytochrome P450 BM3
122. Critical residues involved in FMN binding and catalytic activity in cytochrome P450 BM3
123. Structure of a cytochrome P450-redox partner electron-transfer complex
124. Three-dimensional structure of NADPH-cytochrome P450 reductase: Prototype for FMN- and FAD-containing enzymes
125. Laboratory evolution of peroxide-mediated cytochrome P450 hydroxylation
126. Electrocatalytically driven omega-hydroxylation of fatty acids using cytochrome P450 4A1
127. Application of electrochemistry for P450-catalyzed reactions
128. The interaction of NADPH-P450 reductase with P450: An electrochemical study of the role of the flavin mononucleotide-binding domain
129. Maximizing expression of eukaryotic cytochrome P450s in Escherichia coli
130. A genetically engineered P450 monooxygenase: Construction of the functional fused enzyme between rat cytochrome P450c and NADPH-cytochrome P450 reductase
131. Genetically engineered P450 monooxygenases: Construction of bovine P450c17/yeast reductase fused enzymes
132. Expression of bovine cytochrome P450c21 and its fused enzymes with yeast NADPH-cytochrome P450 reductase in Saccharomyces cerevisiae
133. Expression and enzymatic activity of recombinant cytochrome P450 17α-hydroxylase in E. coli
134. High-level expression in Escherichia coli of enzymatically active fusion proteins containing the domains of mammalian cytochromes P450 and NADPH-P450 reductase flavoprotein
135. Human cytochrome P450 3A4: Enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase
136. Construction of plasmids and expression in E. coli of enzymatically active fusion proteins containing the heme domain of a P450 linked to NADPH-P450 reductase
137. Construction of a human cytochrome P4501A1: RatNADPH-cytochrome P450 reductase fusion cDNA and expression in Escherichia coli, purification and catalytic properties of the enzyme in bacterial cells and after purification
138. The AH locus-genetic differences in toxicity, cancer, mutation, and birth-defects
139. I462V mutation in the human CYP1A1 gene-lack of correlation with either the Msp I 1.9 kB (m2) allele or CYP1A1 inducibility in a 3-generation family of east Mediterranean descent
140. Cytochrome-P450 enzymes
141. Herbicide-resistant tobacco plants expressing the fused enzyme between rat cytochrome P4501A1 (CYP1A1) and yeast NADPH-cytochrome P450 oxidoreductase
142. Mutagenesis study of Asp-290 in cytochrome P450 2B11 using a fusion protein with rat NADPH-cytochrome P450 reductase
143. Putidaredoxin reductase-putidaredoxin-cytochrome P450cam triple fusion protein
144. 3 25 hydroxylase activity
145. Construction and function of fusion enzymes of the human cytochrome-P450scc system
146. Construction and characterisation of a catalytic fusion protein system: P450 11β-adrenodoxin reductase-adrenodoxin
147. + reductase from plant chloroplasts
148. Molecular engineering study on electron transfer from NADPH-P450 reductase to rat mitochondrial P450c27 in yeast microsomes
149. Kinetic studies on a genetically engineered fused enzyme between rat cytochrome P450 1A1 and yeast NADPH-P450 reductase